Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Fatty acid binding protein 3 (FABP3)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

CSF FABP3 levels are increased at early phases of AD , associated with the onset of cognitive deterioration, and, in combination with other biomarkers shows high accuracy in differentiating AD from dementia with Lewy bodies.

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

  1. Chiasserini, D., Biscetti, L., Eusebi, P., Salvadori, N., Frattini, G., Simoni, S., ... &     Engelborghs, S. (2017). Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. Alzheimer's Research & Therapy, 9(1), 52. https://www.ncbi.nlm.nih.gov/pubmed/28750675

  2. “FABP3 fatty acid binding protein 3 [ Homo sapiens (human) ].” https://www.ncbi.nlm.nih.gov/gene/2170

  3. Höglund, K., Kern, S., Zettergren, A., Börjesson-Hansson, A., Zetterberg, H., Skoog, I., & Blennow, K. (2017). Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 7(1), e995. https://www.ncbi.nlm.nih.gov/pubmed/28072416

  4. Sepe, F. N., Chiasserini, D., & Parnetti, L. (2018). Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies. Future Neurology, 13(4), 199-207. https://www.futuremedicine.com/doi/10.2217/fnl-2018-0003